Buy Vyvanse Online

(1 customer review)

$675.00$1,380.00

Name
Vyvanse

Generic Name
Lisdexamfetamine

Dosage Form
Capsules

Dosage Strength
30mg, 40mg, 50mg, 70mg.

Packaging
Packaging is fast and we ship discretely to your doorstep, 24 hours within the united states and Canada plus a 3 days lead time in other continents apart from North America.

Clear

Description

Order Vyvanse Online – Best Place To Order Vyvanse Online Legit And With Fast Overnight Delivery.

ADHD Pharma is the best place for you to Order Vyvanse Online without any prescription, Benefit from our fast overnight delivery services. we only sell FDA approved medications and customer satisfaction is our main goal.
At ADHD Pharma we offer a 100% money back guarantee no questions asked and we ship fast and discretely overnight

Description

Vyvanse (lisdexamfetamine dimesylate) is designed as a capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate. The molecular formula is C15H25N3O•(CH4O3S)2, which corresponds to a molecular weight of 455.60. Lisdexamfetamine dimesylate is a white to off-white powder that is soluble in water (792mg/mL). Vyvanse capsules contain 30 mg, 50 mg and 70 mg of lisdexamfetamine dimesylate and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The capsule shells contain gelatin, titanium dioxide, and one or more of the following: D&C Red #28, D&C Yellow #10, FC&C Blue #1 and FD&C Red .

Indications

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of Vyvanse in the treatment of ADHD was established on the basis of two controlled trials in children aged 6 to 12, who met DSM-IV® criteria for ADHD A diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD; DSM-IV®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, in social, academic, or occupational functioning, and be present in two or more settings, e.g., at school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Side Effects

The premarketing development program for Vyvanse included exposures in a total of 404 participants in clinical trials (348 pediatric patients and 56 healthy adult subjects). Of these, 348 pediatric patients (ages 6 to 12) were evaluated in two controlled clinical studies (one parallel-group and one crossover), one open-label extension study, and one single-dose clinical pharmacology study. The information included in this section is based on data from the 4-week parallel-group controlled clinical trial in pediatric patients with ADHD. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and listings that follow, MedRA terminology has
been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. Adverse events associated with discontinuation of treatment: Ten percent (21/218) of Vyvanse-treated patients discontinued due to adverse events compared to 1% (1/ 72) who received placebo. The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e., leading to discontinuation in at least 1% of Vyvansetreated patients and at a rate at least twice that of placebo) were ECG voltage criteria for ventricular hypertrophy, tic, vomiting, psychomotor hyperactivity, insomnia, and rash (2/218 each; 1%). Adverse events occurring in a controlled trial: Adverse events reported in a 4-week clinical trial in pediatric patients treated with Vyvanse or placebo are presented in the table below. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied. The following adverse events that occurred in at least 5% of the Vyvanse patients and at a rate twice that of the placebo group (Table 1): Upper abdominal pain, decreased appetite, dizziness, dry mouth, irritability, insomnia, nausea, vomiting, and decreased weight.

Contraindications

-Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. Agitated states.
-Patients with a history of drug abuse.
-During or within 14 days following the administration of monoamine oxidase
inhibitors (hypertensive crises may result).

Order Vyvanse Online

Packaging and delivery: At ADHD Pharma Order Vyvanse Online without any written prescription, fast and Discreet overnight shipping 48 hours within USA and Canada and 2 to 3 days worldwide with TNT, UPS, DHL and FedEx…

Order Vyvanse Online – Best Place To Order Vyvanse Online Legit And With Fast Overnight Delivery.

Additional information

Dosage Quantity

120 30mg pills, 120 40mg pills, 120 50mg pills, 120 70mg pills, 150 30mg pills, 150 40mg pills, 150 50mg pills, 150 70mg pills, 180 30mg pills, 180 40mg pills, 180 50mg pills, 180 70mg pills, 90 30mg pills, 90 40mg pills, 90 50mg pills, 90 70mg pills

1 review for Buy Vyvanse Online

  1. Chris stew

    Unbelievable!, delivery on time as promised. Splendid!

Add a review

Your email address will not be published. Required fields are marked *